Breaking News Instant updates and real-time market news.

REPH

Recro Pharma

$8.84

-0.08 (-0.90%)

08:10
10/03/16
10/03
08:10
10/03/16
08:10

Recro Pharma coverage assumed with a Buy at Brean Capital

Brean Capital analyst Difei Yang assumed coverage on Recro Pharma with a Buy rating citing upcoming catalysts and its lead product candidate which could serve as a non-opioid alternative for pain management. Yang placed a $21 price target on Recro Pharma shares, which is reduced from the firm's prior price target of $28.

REPH Recro Pharma
$8.84

-0.08 (-0.90%)

08/29/16
JANY
08/29/16
INITIATION
Target $21
JANY
Buy
Recro Pharma initiated with a Buy at Janney Capital
Janney Capital analyst Ken Trbovich initiated Recro Pharma with a Buy rating and $21 fair value estimate.
08/29/16
JANY
08/29/16
INITIATION
JANY
Buy
Recro Pharma initiated with a Buy at Janney Capital
Target $21.
08/29/16
08/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Sell at Axiom by analyst Victor Anthony, who set an $80 price target on shares of the streaming service operator. The company's is seeing rising competition and diminishing pricing power, Anthony tells investors in a research note. He adds that rising content costs will pressure Netflix's ability to meet Street estimates. 2. Invuity (IVTY) initiated with a Buy rating and $25 price target by Craig-Hallum analyst Charles Haff, who believes the company's surgical lighting products offer higher quality resolution and are safer and more effective than the current standard of care in minimally-invasive procedures. 3. Recro Pharma (REPH) initiated by Janney Capital analyst Ken Trbovich with a Buy rating and $21 fair value estimate. 4. Neuralstem (CUR) initiated by Roth Capital analyst Joseph Pantginis with a Buy rating and $1.20 price target. 5. At Home Group (HOME) initiated with an Outperform rating at William Blair and with a Buy rating and $20 price target at Jefferies. To see The Fly's full Street Research coverage, Reference Link
09/16/16
ROTH
09/16/16
INITIATION
Target $24
ROTH
Buy
Recro Pharma initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry started Recro Pharma with a Buy rating and $24 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.